| 1 Subjective dry eye symptoms, as measured using a validated dry eye questionnaire at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
3 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 1.1 Unit of analysis was study eye |
2 |
144 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.33 [‐2.56, 1.89] |
| 1.2 Unit of analysis was study participant |
1 |
42 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.60 [‐6.72, ‐2.48] |
| 2 Sodium fluorescein tear break‐up time at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 2.1 Unit of analysis was study eye |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 2.2 Unit of analysis was study participant |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 3 Non‐invasive tear break‐up time (NIBUT) at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.1 Unit of analysis was the study eye |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 3.2 Unit of analysis was the study participant |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 4 Tear osmolarity at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5 Lipid layer thickness at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 6 Eyelid irregularity at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 7 Eyelid telangiectasia at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 8 Meibomian gland orifice plugging at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 9 Meibomian gland dropout at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 10 Corneal sodium fluorescein staining at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
